v3.26.3
Consolidated Balance Sheets - USD ($)
Jul. 31, 2026
Jul. 31, 2025
CURRENT ASSETS:    
Cash and cash equivalents $ 9,852,435 $ 10,493,808
Short-term investments 10,688,277 7,372,473
Amounts receivable and prepaid expenses 1,504,228 2,060,295
Total current assets 22,044,940 19,926,576
NON-CURRENT ASSETS:    
Equity investment in BC Therapeutics 730,028 524,278
Intangible assets, net 169,254 184,525
Property and equipment, net 319,804 296,819
Long term prepaid expenses 315,703 717,508
Total non-current assets 1,534,789 1,723,130
Total assets 23,579,729 21,649,706
CURRENT LIABILITIES:    
Trade payables 6,994,539 3,283,703
Accrued expenses and other payables 987,109 694,285
Total current liabilities 7,981,648 3,977,988
NON-CURRENT LIABILITIES:    
Warrant liability 38,939 337,672
Total non-current liabilities 38,939 337,672
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY (DEFICIT):    
Share Capital of no par value – Authorized: unlimited at July 31, 2026 and 2025; Issued and outstanding: 8,708,029 and 1,883,906 shares at July 31, 2026 and 2025, respectively 120,914,482 101,739,923
Share-based payment reserve 11,879,317 10,316,140
Warrant reserve 30,405,598 17,719,026
Accumulated other comprehensive loss (138,684) (138,684)
Non-controlling interest (841,745) (546,795)
Accumulated deficit (146,659,826) (111,755,564)
Total shareholders’ equity 15,559,142 17,334,046
Total liabilities and shareholders’ equity $ 23,579,729 $ 21,649,706